Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + Dexamethasone in Relapsed/Refractory DLBCL
NCT00474188Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- May 2007
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Celgene Corporation. Primary endpoint: Tumor Response Rate at 1 year. Started May 2007; status: terminated.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00474188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00474188.